MX2021014274A - Moleculas de union anti-tdp-43 y usos de las mismas. - Google Patents
Moleculas de union anti-tdp-43 y usos de las mismas.Info
- Publication number
- MX2021014274A MX2021014274A MX2021014274A MX2021014274A MX2021014274A MX 2021014274 A MX2021014274 A MX 2021014274A MX 2021014274 A MX2021014274 A MX 2021014274A MX 2021014274 A MX2021014274 A MX 2021014274A MX 2021014274 A MX2021014274 A MX 2021014274A
- Authority
- MX
- Mexico
- Prior art keywords
- tdp
- disease
- binding molecules
- present
- tardb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Proteínas de unión a ADN de respuesta transactiva con un peso molecular de 43 kDa (TARDB o también TDP-43). Se describen moléculas de unión específicas de TDP-43, en particular con anticuerpos anti-TDP-43 o un fragmento de unión al antígeno o un derivado de los mismos y sus usos. Asimismo se proveen medios y métodos para diagnosticar, prevenir, aliviar y/o tratar una enfermedad, un trastorno y/o una anomalía asociada con agregados de TDP-43 que incluye, pero en un sentido no taxativo, demencia frontotemporal (FTD), esclerosis lateral amiotrófica (ALS), enfermedad de Alzheimer (AD), enfermedad de Parkinson (PD), encefalopatía traumática crónica, y encefalopatía TDP-43 con predominio límbico, relacionada con la edad (LATE).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19176314 | 2019-05-23 | ||
EP19195916 | 2019-09-06 | ||
EP19207839 | 2019-11-07 | ||
EP20161060 | 2020-03-04 | ||
PCT/EP2020/064335 WO2020234473A1 (en) | 2019-05-23 | 2020-05-22 | Anti-tdp-43 binding molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014274A true MX2021014274A (es) | 2022-01-06 |
Family
ID=70779783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014274A MX2021014274A (es) | 2019-05-23 | 2020-05-22 | Moleculas de union anti-tdp-43 y usos de las mismas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220315648A1 (es) |
EP (1) | EP3972692A1 (es) |
JP (1) | JP2022533432A (es) |
KR (1) | KR20220012270A (es) |
CN (1) | CN114008073A (es) |
AU (1) | AU2020278907A1 (es) |
BR (1) | BR112021023487A2 (es) |
CA (1) | CA3137882A1 (es) |
CL (1) | CL2021003027A1 (es) |
IL (1) | IL288314A (es) |
MX (1) | MX2021014274A (es) |
SG (1) | SG11202112453TA (es) |
TW (1) | TW202110879A (es) |
WO (1) | WO2020234473A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112920264B (zh) * | 2021-02-08 | 2022-07-05 | 武汉大学 | Tdp-43蛋白的o-糖基化突变体及其应用 |
WO2022174036A2 (en) * | 2021-02-11 | 2022-08-18 | Mayo Foundation For Medical Education And Research | Methods and materials for treating tdp-43 proteinopathies |
WO2023156549A1 (en) | 2022-02-16 | 2023-08-24 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
CN117126269B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种1型人博卡病毒型别特异性抗体及其应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
IL154751A0 (en) | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
DE60336548D1 (de) | 2002-04-09 | 2011-05-12 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
SI2289936T1 (sl) | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Imunoglobulinske variante in njihove uporabe |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
LT2380911T (lt) | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
WO2008151055A1 (en) | 2007-06-01 | 2008-12-11 | Mayo Foundation For Medical Education And Research | Diagnosing neurodegenerative diseases |
EP3527220A1 (en) | 2010-08-12 | 2019-08-21 | AC Immune S.A. | Vaccine engineering |
US9687447B2 (en) | 2010-10-26 | 2017-06-27 | Ac Immune S.A. | Method for preparing liposome-based constructs |
KR102032080B1 (ko) | 2011-10-28 | 2019-10-15 | 바이오겐 인터내셔널 뉴로사이언스 게엠베하 | Tdp-43 특이적 결합 분자 |
CN104284675B (zh) | 2012-03-16 | 2017-07-18 | 科瓦根股份公司 | 具有抗肿瘤活性的新颖结合分子 |
FI3334761T3 (fi) * | 2015-08-13 | 2023-08-14 | Univ New York | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa |
-
2020
- 2020-05-22 WO PCT/EP2020/064335 patent/WO2020234473A1/en active Application Filing
- 2020-05-22 EP EP20727297.2A patent/EP3972692A1/en active Pending
- 2020-05-22 US US17/613,444 patent/US20220315648A1/en active Pending
- 2020-05-22 CN CN202080038441.4A patent/CN114008073A/zh active Pending
- 2020-05-22 AU AU2020278907A patent/AU2020278907A1/en active Pending
- 2020-05-22 TW TW109117264A patent/TW202110879A/zh unknown
- 2020-05-22 SG SG11202112453TA patent/SG11202112453TA/en unknown
- 2020-05-22 JP JP2021569353A patent/JP2022533432A/ja active Pending
- 2020-05-22 CA CA3137882A patent/CA3137882A1/en active Pending
- 2020-05-22 BR BR112021023487A patent/BR112021023487A2/pt unknown
- 2020-05-22 MX MX2021014274A patent/MX2021014274A/es unknown
- 2020-05-22 KR KR1020217040767A patent/KR20220012270A/ko unknown
-
2021
- 2021-11-16 CL CL2021003027A patent/CL2021003027A1/es unknown
- 2021-11-22 IL IL288314A patent/IL288314A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN114008073A (zh) | 2022-02-01 |
WO2020234473A1 (en) | 2020-11-26 |
TW202110879A (zh) | 2021-03-16 |
CA3137882A1 (en) | 2020-11-26 |
IL288314A (en) | 2022-01-01 |
US20220315648A1 (en) | 2022-10-06 |
AU2020278907A1 (en) | 2022-01-20 |
CL2021003027A1 (es) | 2022-06-24 |
BR112021023487A2 (pt) | 2022-02-08 |
KR20220012270A (ko) | 2022-02-03 |
EP3972692A1 (en) | 2022-03-30 |
JP2022533432A (ja) | 2022-07-22 |
SG11202112453TA (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014274A (es) | Moleculas de union anti-tdp-43 y usos de las mismas. | |
MX2020006956A (es) | Moleculas de union a tdp-43 mal plegadas. | |
PH12018502613A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
MX2019013172A (es) | Composiciones y metodos para tratar la enfermedad de huntington. | |
MX2018000505A (es) | Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos. | |
MX356800B (es) | Anticuerpo tau humanizado. | |
WO2016024205A8 (en) | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene | |
WO2010004434A3 (en) | Method of promoting neurogenesis | |
MX2019009382A (es) | Anticuerpo anti-humano de anexina a1. | |
MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
EA200901067A1 (ru) | Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов | |
PH12019502869A1 (en) | Agents, uses and methods for treatment | |
AU2016210835A8 (en) | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders | |
MX2009012948A (es) | Nuevas indicaciones para la terapia anti-il-1-beta. | |
WO2017197253A3 (en) | Peptides and methods for treating neurodegenerative disorders | |
MX2021012608A (es) | Nuevas moleculas para terapia y diagnostico. | |
JO3188B1 (ar) | بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل | |
PH12020551805A1 (en) | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof | |
WO2012138102A3 (ko) | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 | |
ZA202110285B (en) | Antibodies and methods of use | |
MX2014000113A (es) | Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. | |
EA202193215A1 (ru) | Связывающие молекулы к tdp-43 и варианты их применения | |
MX2022001604A (es) | Anticuerpos anti bdca-2. | |
WO2022204362A3 (en) | Compositions and methods for treating a neurodegenerative or developmental disorder | |
AR118999A1 (es) | Moléculas de unión anti-tdp-43 y usos de las mismas |